Phase 2 PIK3CA-Related Overgrowth Spectrum (PROS) Clinical Trials
3 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–3 of 3 trials
Recruiting
Phase 2
A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation
PIK3CA MutationVascular MalformationsPIK3CA-Related Overgrowth Spectrum (PROS)+4 more
Relay Therapeutics, Inc.277 enrolled31 locationsNCT06789913
Recruiting
Phase 2
EPIK-P4: A Phase II Single-arm Study to Assess the Efficacy, Safety and Pharmacokinetics of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum (PROS)
PIK3CA-Related Overgrowth Spectrum (PROS)
Novartis Pharmaceuticals104 enrolled30 locationsNCT06997588
Recruiting
Phase 1Phase 2
Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CYH33 in Patients With PIK3CA-related Overgrowth Spectrum (PROS) and PIK3CA-related Vascular Malformations (PRVM)
PIK3CA-Related Overgrowth Spectrum (PROS)PIK3CA-related Vascular Malformations (PRVM)
Haihe Biopharma Co., Ltd.141 enrolled4 locationsNCT06975618